"HIRONIC: U.S. FDA Clearance and Recurring Consumables Revenue Set to Grow"

Independent research firm Bullet projected on October 15 that HIRONIC's consolidated revenue and earnings would rise significantly this year.

In a report released that day, Bullet researcher Ahn Byungwook said, "Consolidated revenue in the first half of this year rose 23.6% year over year to KRW 20.4 billion, while operating profit increased 33.5% to KRW 2.6 billion. The company posted its highest-ever first-half revenue and its highest operating profit in 11 years." He added, "It sold 476 devices in the first half alone, more than half of the 744 units sold last year."

Revenue from consumables rose 33%, from KRW 8.4 billion in 2024 to KRW 11.2 billion in 2025. It reached KRW 5.8 billion in the first half of this year. The business is structured to create a virtuous cycle of recurring revenue growth, as demand for consumables such as cartridges and nozzles increases with new device sales, the report said.

Synerjet Pro has obtained U.S. Food and Drug Administration (FDA) clearance for transcutaneous electrical stimulation, in addition to its existing electrosurgery clearance. This gives the company the necessary approvals to sell the device for both functions in the United States.

In July this year, HIRONIC signed exclusive distribution agreements for Venus Concept and V-RO lifting in the United States and Canada. Initial shipments followed shortly after the agreements were signed. Venus Concept, a Canadian medical aesthetics device company, can sell directly through its own sales teams, without distributors, in 11 countries including the United States, enabling it to secure large-volume orders in a single deal.

Researcher Ahn said, "Both devices are expected to broaden the company's growth base as new revenue sources added to its existing flagship product lineup. We expect a significant increase in consolidated revenue and earnings this year."

This content was produced with the assistance of AI translation services.